mercredi 24 octobre 2018

Onco Actu du 24 octobre 2018 - Spécial ESMO

5.6.10 ESMO - Vessie

Merck’s KEYTRUDA® (pembrolizumab) Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care [Merck]

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer [BMS]

Addition of Ipilimumab Improves Nivolumab Response in PD-L1 Unselected Patients with Platinum-Pretreated Metastatic Urothelial Cancer [ESMO]

5.6.11 ESMO- Rein

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma [BMS]

Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma [Exelixis]

Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma [Exelixis]

ESMO18: Pfizer preps for Bristol-Myers Squibb showdown with Bavencio kidney cancer combination data [FiercePharma]

Molecular Characteristics of Clinical Response to Atezolizumab plus Bevacizumab Differ from Sunitinib in IMmotion151 Study [ESMO]

Cabozantinib Improves Survival Over Everolimus or Sunitinib in PD-L1 Unselected Patients with mRCC [ESMO]

5.6.13 ESMO - Prostate

Prostate cancer radiotherapy could have benefits even after the disease has spread [Cancer Research UK]

Prostate cancer: radiotherapy could extend thousands of lives, study finds [The Guardian]

ESMO: Clovis bolsters Rubraca's PARP-leading prostate cancer bid with big-time response data [FiercePharma]

Clovis Oncology Presents Initial Results from the Ongoing Rubraca® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer (mCRPC) at ESMO 2018 Congress [Clovis Oncology]

#ESMO18: Crowned with a breakthrough title, Clovis takes an early lead as it races for a fast OK for Rubraca in prostate cancer [EndPoints]

5.6.14 ESMO - Ovaire

ESMO18: Mammoth Lynparza survival win puts AstraZeneca, Merck in line for $1B launch [FiercePharma]

SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer [AstraZeneca]

5.6.17 ESMO - Foie

#ESMO18: Cardio dreams blighted, Novartis showcases its “blockbuster” ambitions for radiopharmaceuticals [EndPoints]

5.6.19 ESMO - Médecine personnalisée

Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress [Loxo Oncology]

Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients [Genomic Health]

ESMO18: As larotrectinib nears FDA decision day, Bayer and Loxo post latest positive data [FierceBiotech]

Expanded larotrectinib data confirm findings on efficacy and safety in adult and pediatric patients with TRK fusion cancer across various tumor types [Bayer]

Entrectinib Is Effective Across NTRK Fusion Positive Solid Tumour Types [ESMO]

Roche’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours [Roche]

Roche takes on Loxo, Bayer in gene-defined cancer class [Reuters]

5.6.2 ESMO - Divers

Carboplatin Plus Paclitaxel Respresents a New Standard of Care for Patients with Squamous Cell Carcinoma of the Anal Canal [ESMO]

Social vulnerability and medical skepticism top factors limiting adherence to cancer screening: an online survey [ESMO 2018 Press Release]

First-in-Class NBTXR3 Provides a New Option for Preoperative Treatment in Patients with Locally Advanced STS (Act-In-Sarc) [ESMO]

ESMO Award honours Jean-Charles Soria [ESMO Press Release]

Huge variations between countries in time for reimbursement decisions on new cancer drugs [ESMO 2018 Press Release]

5.6.3 ESMO - Trastuzumab

Study indicates HER2+ early breast cancers where shorter-course trastuzumab could be an option [ESMO 2018 Press Release]

5.6.4 ESMO - Poumon

New data on mechanisms of acquired resistance after 1st-line Tagrisso in NSCLC support initiation of ORCHARD trial to explore post-progression treatment options [AstraZeneca]

The final analysis of SPLENDOUR trial did not show improvement in overall survival in advanced Non-Small Lung Cancer [EORTC]

Patients with Lung Adenocarcinomas and Specific Uncommon EGFR Mutations Have Improved Survival with Chemotherapy Compared to TKIs [ESMO]

Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC [Novartis]

Promising Anti-Tumour Activity Demonstrated with First-Line Nazartinib in Adult Patients with EGFR-Mutant NSCLC [ESMO]

Early Results From a Ground Breaking Study of Tumour Evolution Identifies Genetic Drivers in NSCLC [ESMO] ESMO - Poumon (atezolizumab)

ESMO: Roche's latest Tecentriq lung results underscore Avastin's talents, executive says [FiercePharma]

B-F1RST Study Evaluates Blood-Based Tumour Mutational Burden as a Biomarker of Atezolizumab Activity in First-Line NSCLC Treatment [ESMO]

Roche’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone [Roche]

Roche lands Tecentriq trial win, still trails Merck in lung cancer [Reuters] ESMO - Poumon (crizotinib, ...)

Roche’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer [Roche]

Alectinib Provides Superior Outcomes Compared with Crizotinib in Asian Patients with Advanced ALK-positive NSCLC, with and without CNS Metastases [ESMO]

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer [Takeda]

5.6.5 ESMO - Mélanome & Peau

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma [BMS]

Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma [Novartis]

Optimal Neo-Adjuvant Combination of Ipilimumab and Nivolumab Devised in High Risk Melanoma [ESMO] ESMO - Sein (triple négatif)

Roche scores win in slowing aggressive type of breast cancer [Reuters]

ESMO: Roche's Tecentriq posts 'unprecedented' benefit in triple-negative breast cancer [FiercePharma]

A New Type of Treatment Shows Promise Against Aggressive Breast Cancer [Time]

Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer [Roche]

Not So Fast With Immune Therapy For Breast Cancer [Forbes]

Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds [NY Times] ESMO - Sein (alpelisib)

Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone [Novartis]

ESMO18: Novartis PI3K combo therapy boosts survival in subset of breast cancer patients [FierceBiotech]

#ESMO18: Novartis claims a key win in breast cancer with PI3K drug alpelisib [EndPoints]

Novartis drug cut death risk by 35 percent in gene mutation breast cancer [Reuters] ESMO - Sein (palbociclib)

ESMO: Pfizer's narrow Ibrance survival miss could still sway doctors in its favor, executives say [FiercePharma]

Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer [Pfizer]

5.6.7 ESMO - Immunothérapies

ESMO18: Merck's Keytruda, alone and in combo, makes its case for earlier use in head and neck cancer [FiercePharma]

Immunotherapy May Be a New Treatment Option for Patients with Chemotherapy Resistant Gestational Trophoblastic Neoplasias [ESMO]

5.6.8 ESMO - Côlon-rectum

ESMO18: Bristol-Myers Squibb eyes lead in rare colorectal cancer with new Opdivo results [FiercePharma]

Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer [BMS]

Major response to immunotherapy in early-stage mismatch repair deficient colon cancer [ESMO 2018 Press Release]

Immunotherapy may become new first line treatment in some metastatic colorectal cancers [ESMO 2018 Press Release]